A tale of two vaccines: Lessons from polio that could inform the development of an HIV vaccine

AIDS

Volumn 27, Issue 1, 2013, Pages 1-5

  Esparza, José ^a  

^a BILL AND MELINDA GATES FOUNDATION   (United States)

Author keywords

AIDS vaccines; HIV vaccines; opinion of experts; paradigm change; polio vaccines; political support; private foundations; Salk polio vaccine trial

Indexed keywords

ANTIRETROVIRUS AGENT; FORMALDEHYDE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INACTIVATED VACCINE; INFLUENZA VACCINE; LIVE VACCINE; ORAL POLIOMYELITIS VACCINE; PLACEBO; POLIOMYELITIS VACCINE;

CELLULAR IMMUNITY; CLINICAL EVALUATION; CLINICAL PROTOCOL; CLINICAL TRIAL (TOPIC); DRUG DESIGN; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; GOVERNMENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPOTHESIS; IMMUNOGENICITY; INCIDENCE; INFLUENZA; KNOWLEDGE; MEDICAL EXPERT; MEDICAL INFORMATION; MEDICAL SOCIETY; NONHUMAN; PASSIVE IMMUNIZATION; POLIOMYELITIS; POLIOMYELITIS VIRUS; POLITICS; PREVENTIVE MEDICINE; PRIORITY JOURNAL; PUBLIC HEALTH; REVIEW; SCIENTIFIC LITERATURE; THAILAND; VIRUS REPLICATION; VIRUS STRAIN;

AIDS VACCINES; CLINICAL TRIALS AS TOPIC; EXPERT TESTIMONY; FEMALE; HEALTH SERVICES NEEDS AND DEMAND; HISTORY, 20TH CENTURY; HUMANS; MALE; POLIOMYELITIS; POLIOVIRUS VACCINE, INACTIVATED; RESEARCH DESIGN; VIRAL LOAD;

EID: 84871616188     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e328359f2c1     Document Type: Review

References (33)

1. Cohen J. Shots in the dark: the wayward search for an HIV vaccine. New York: W. W. Norton & Company; 2001.
2. Francis T, Napier JA, Voight RB, Hemphill FM, Wenner HA, Korns RF, et al. Evaluation of the 1954 field trial of poliomyelitis vaccine, final report. Ann Arbor, Michigan: Poliomyelitis Vaccine Evaluation Center, University of Michigan; 1957.
3. Oshinsky DM. Polio: an American story. New York: Oxford University Press; 2005.
4. Rerks-Ngarn S, Pitisuttithum P, Nityaphan S, Kaerwkungwal J, Chiu J, Paris R, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009; 361:2209-2220.
5. Burton DR, Desrosiers RC, Doms RW, Feinberg MB, Gallo RC, Hahn B, et al. Public health. a sound rationale needed for phase III HIV-1 vaccine trials. Science 2004; 303:316. (Pubitemid 38095757)
6. Cohen J. Beyond Thailand: making sense of a qualified AIDS vaccine 'success'. Science 2009; 326:652-653.
7. Haynes BF, Gilbert PB, McElrath MJ, Zolla-Pazner S, Tomaras GD, Alam SM, et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med 2012; 366:1275-1286.
8. Levy J. HIV and the pathogenesis of AIDS. 3rd ed. Washington, DC: American Society for Microbiology Press; 2007.
9. Virgin HW, Walker BD. Immunology and the elusive AIDS vaccine. Nature 2010; 464:224-231.
10. Walker BD, Ahmed R, Plotkin S. Moving ahead an HIV vaccine: use both arms to beat HIV. Nature Med 2011; 17:1194-1195.
11. Levy JA. The transmission of AIDS: the case of the infected cell. JAMA 1988; 259:3037-3038.
12. Brodie M, Park WH. Active immunization against poliomyelitis. Am J Pub Health 1936; 26:119-125.
13. Kolmer JA, Klugh GF, Rule AM. A successful method for vaccination against acute anterior poliomyelitis. Further report. JAMA 1935; 104:456-460.
14. Nathanson N. David Bodian's contribution to the development of poliovirus vaccine. Am J Epidemiol 2005; 161:207-212. (Pubitemid 40223508)
15. Enders JF, Weller TH, Robbins FC. Cultivation of the lansing strain of poliomyelitis virus in cultures of various human embryonic tissues. Science 1949; 109:85-87.
16. Hilleman MR. A simplified vaccinologist'svaccinology and the pursuit of a vaccine against AIDS. Vaccine 1988; 16:778-793.
17. Buchbinder SP, Mehrotra DV, Duerr A, Fitzgerald DW, Mogg R, Li D, et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the STEP Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 2008; 372:1881-1893.
18. Kaiser J. Review of vaccine failure prompts a return to basics. Science 2008; 320:30-31. (Pubitemid 351490732)
19. Fauci AS, Johnston MI, Dieffenbach CW, Burton DR, Hammer SM, Hoxie JA, et al. HIV vaccine research: the way forward. Science 2008; 321:530-532.
20. Francis T, Salk JE, Pearson HE, Brown PN. Protective effect of vaccination against induced influenza A. J Clin Invest 1945; 24:536-546.
21. Salk JE. Considerations in the preparation and use of poliomyelitis virus vaccine. JAMA 1955; 158:1239-1248.
22. Duerr A, Huang Y, Buchbinder S, Coombs RW, Sanchez J, del Rio C, et al. Extended follow-up confirms early vaccine-enhanced risk of HIV acquisition and demonstrates waning effect over time among participants in a randomized trial of recombinant adenovirus HIV vaccine (STEP study). J Infect Dis 2012; 206:258-266.
23. Letvin NL. Moving forward in HIV vaccine development. Science 2009; 326:1196-1198.
24. Blume S, Geesink I. A brief history of polio vaccines. Science 2000; 288:1593-1594. (Pubitemid 30387415)
25. Hortsmann DM. The Sabin live poliovirus vaccination trials in the USSR, 1959. Yale J Biol Med 1991; 64:499-512.
26. Esparza J, Russell ND, McCutchan FE. Controversies in Science and Technology. In: Kleinman DL, Delbome J, Cloud-Hansen KA, Handelsman J, editors. The long road to an HIV vaccine. New York: Mary Ann Liebert Inc, Publishers; 2010. pp. 44-76
27. Rinaldo CR. Passive immunization against poliomyelitis: The Hammon gamma globulin field trials, 1951-1953. Am J Pub Health 2005; 95:790-799.
28. Shattock RJ, Warren M, McCormack S, Hankins CA. Turning the tide against HIV. Science 2011; 333:42-43.
29. Prejean J, Song R, Hernandez A, Ziebell R, Green T, Walker F, et al. Estimated HIV incidence in the United States, 2006-2009. PLoS One 2011:e17502.
30. Lawler A, Cohen J. A deadline for an AIDS vaccine. Science 1997; 276:1184.
31. Klausner RD, Fauci AS, Corey L, Nabel GJ, Gayle H, Berkley S, et al. The need for a global HIV vaccine enterprise. Science 2003; 300:2036-2039. (Pubitemid 36760117)
32. Wilson JR. Margin of safety: The story of poliomyelitis vaccine. London: Collins; 1963.
33. HIV vaccines & microbicides resource tracking working group. Capitalizing on scientific progress: Investment in HIV prevention R&D in 2010. New York: AVAC: Global Advocacy for HIV Prevention; 2011.